Experimental Medicine - Developing biomarkers in early discovery to bridge preclinical and clinical development By Dr Robert Dix In today's pharmaceutical research and development environment a major problem is the transition of too many drugs to later stages of development with insufficient and/or inadequate information (eg efficacy, dosing), resulting in high attrition and consumption of […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!